Nyxoah Prices $95 Million Underwritten Public Offering

Medical technology firm Nyxoah announced on June 5, 2026, that it has priced an underwritten public offering of its ordinary shares, raising approximately $95 million. The company intends to use the net proceeds for general corporate purposes, including advancing its commercialization efforts and funding research and development.

The offering comes as Nyxoah enters what it describes as a new chapter of long-term value creation. Earlier in June, the company announced plans for a transition to a U.S.-based CEO to accelerate the commercial launch of its Genio system in the United States.

Nyxoah, listed on both Euronext Brussels and Nasdaq (NYXH), specializes in developing treatment alternatives for obstructive sleep apnea (OSA). Its Genio system is a key product aimed at offering an alternative to existing treatment modalities for the condition.

The company's first-quarter 2026 financial results indicated strong sequential revenue growth in the U.S., attributed to the launch of the Genio system. This latest financing is expected to bolster Nyxoah's capacity to expand its market presence and further its development of sleep disorder treatment solutions.